| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2011 | EP2314587A1 Nitrogenated heterocyclic compound |
| 04/27/2011 | EP2314586A1 2-Acylaminothiazole derivative or salt thereof |
| 04/27/2011 | EP2314585A1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| 04/27/2011 | EP2314584A1 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 04/27/2011 | EP2314582A1 Heterocyclic compounds as antiviral agents |
| 04/27/2011 | EP2314578A1 Cinchonidine salt of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid, useful as intermediate in the preparation of cannabinoid CB1 neutral antagonists |
| 04/27/2011 | EP2314576A1 Phenyl derivatives as PPAR agonists |
| 04/27/2011 | EP2314575A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 04/27/2011 | EP2314571A2 Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| 04/27/2011 | EP2314569A1 Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| 04/27/2011 | EP2314322A1 Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |
| 04/27/2011 | EP2314321A1 Formulations comprising antisense nucleotides to connexins |
| 04/27/2011 | EP2314319A1 Colon Cleansing Compositions |
| 04/27/2011 | EP2314301A2 Sensitization of chemotherapeutic agent-resistant neoplastic cells with various viruses |
| 04/27/2011 | EP2314299A1 Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| 04/27/2011 | EP2314298A1 Microparticles comprising diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
| 04/27/2011 | EP2314297A1 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 04/27/2011 | EP2314296A1 Orally Disintegrating Tablets of Betahistine |
| 04/27/2011 | EP2314295A1 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| 04/27/2011 | EP2314294A2 3,3'-diindolylmethane immune activating compositions |
| 04/27/2011 | EP2314293A1 Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases |
| 04/27/2011 | EP2314292A1 Endoparasiticidal compositions |
| 04/27/2011 | EP2314291A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/27/2011 | EP2314290A1 Use of iron for treating attention deficit hyperactivity disorder in children |
| 04/27/2011 | EP2314289A1 Gaba receptor mediated modulation of neurogenesis |
| 04/27/2011 | EP2314288A1 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| 04/27/2011 | EP2314285A1 Lipophilic drug delivery vehicle and methods of us thereof |
| 04/27/2011 | EP2314284A2 Cannabinoid liquid formulations for mucosal administration |
| 04/27/2011 | EP2314283A1 Composition comprising anisic acid and an acid buffer |
| 04/27/2011 | EP2314272A1 Stable hydroalcoholic compositions |
| 04/27/2011 | EP2313783A2 Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |
| 04/27/2011 | EP2313506A1 Antagonists of nr2f6 for augmenting the immune response |
| 04/27/2011 | EP2313505A2 Compositions and methods for inhibiting expression of tgf-beta receptor genes |
| 04/27/2011 | EP2313431A2 Long-acting interferons and derivatives thereof and methods thereof |
| 04/27/2011 | EP2313424A2 Anionic pregnane compounds, method for their producing and use of them |
| 04/27/2011 | EP2313419A1 Novel compounds and methods for their production |
| 04/27/2011 | EP2313418A1 Thienyl- and furanyl-isoquinolinones and methods for using them |
| 04/27/2011 | EP2313417A1 Angiotensin ii receptor antagonists |
| 04/27/2011 | EP2313414A2 Kinase inhibitors and methods of use |
| 04/27/2011 | EP2313413A1 Pyrazolo [1, 5-a] pyrimidine derivatives |
| 04/27/2011 | EP2313412A1 Novel derivatives of pyrroloindole inhibitors of hsp90, compositions containing same, and use thereof |
| 04/27/2011 | EP2313411A1 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
| 04/27/2011 | EP2313410A1 Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases |
| 04/27/2011 | EP2313408A1 Diketopiperidine derivatives as hiv attachment inhibitors |
| 04/27/2011 | EP2313407A1 cMET INHIBITORS |
| 04/27/2011 | EP2313406A2 4-dimethylaminophenyl substituted napththyridines und their use as medicine |
| 04/27/2011 | EP2313404A1 Quinuclidine carbonate derivatives and medicinal composition thereof |
| 04/27/2011 | EP2313403A2 Thiazolyl piperdine derivatives |
| 04/27/2011 | EP2313402A1 Heterocyclic urea derivatives and methods of use thereof |
| 04/27/2011 | EP2313400A1 Synthesis of metabolically stable agents for alcohol and drug abuse |
| 04/27/2011 | EP2313399A1 Thiophene or thiazole derivatives and their use as pi3k inhibitors |
| 04/27/2011 | EP2313398A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| 04/27/2011 | EP2313397A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| 04/27/2011 | EP2313395A1 Pyridone and pyridazone analogues as gpr119 modulators |
| 04/27/2011 | EP2313394A1 Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/27/2011 | EP2313393A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 04/27/2011 | EP2313392A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 04/27/2011 | EP2313391A1 Isoquinolinone derivatives as nk3 antagonists |
| 04/27/2011 | EP2313384A1 Phenyl-alkyl piperazines having a modulating activity of tnf |
| 04/27/2011 | EP2313382A1 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
| 04/27/2011 | EP2313380A1 Oxadiazole derivatives for treating diabetes |
| 04/27/2011 | EP2313378A1 Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| 04/27/2011 | EP2313376A2 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof |
| 04/27/2011 | EP2313375A1 Tetrahydrocinnolines as 11 beta hsd1 inhibitors for diabetes |
| 04/27/2011 | EP2313374A1 6-substituted isoquinolines and isoquinolinones |
| 04/27/2011 | EP2313373A1 Heterocyclic derivatives that are used in the treatment of neurodegenerative diseases |
| 04/27/2011 | EP2313372A1 Aminopyridine kinase inhibitors |
| 04/27/2011 | EP2313369A2 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs |
| 04/27/2011 | EP2313368A2 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs |
| 04/27/2011 | EP2313367A2 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs |
| 04/27/2011 | EP2313366A2 Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts |
| 04/27/2011 | EP2313363A2 Lipid compounds for supression of tumorigenesis |
| 04/27/2011 | EP2313360A1 Compounds for the treatment of metabolic diseases |
| 04/27/2011 | EP2313114A2 A drug powder for inhalation administration and a process thereof |
| 04/27/2011 | EP2313111A1 Toll-like receptor agonist formulations and their use |
| 04/27/2011 | EP2313104A1 Thiolated chitosan gel |
| 04/27/2011 | EP2313103A1 Method of treating blepharitis |
| 04/27/2011 | EP2313102A2 Bycyclic nucleosides and nucleotides as therapeutic agents |
| 04/27/2011 | EP2313101A1 Functional micelles for hard tissue targeted delivery of chemicals |
| 04/27/2011 | EP2313100A1 Inhibitors of the plasmodial surface anion channel as antimalarials |
| 04/27/2011 | EP2313099A2 Use of rifalazil to treat colonic disorders |
| 04/27/2011 | EP2313098A1 Methods and systems for evaluating memory agents |
| 04/27/2011 | EP2313097A2 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 04/27/2011 | EP2313096A1 New compounds v |
| 04/27/2011 | EP2313095A2 Methods and products for treating proliferative diseases |
| 04/27/2011 | EP2313094A1 New pyridine derivatives as leptin receptor modulator mimetics |
| 04/27/2011 | EP2313093A2 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 04/27/2011 | EP2313092A1 Polyunsaturated fatty acids for improving vision |
| 04/27/2011 | EP2313091A1 Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| 04/27/2011 | EP2313090A1 Novel sulphur containing lipids for use as food supplement or as medicament |
| 04/27/2011 | EP2313088A2 Oral pharmaceutical formulation for omeprazole comprising a specific separation layer |
| 04/27/2011 | EP2313087A1 Pharmaceutical dosage form for immediate release of an indolinone derivative |
| 04/27/2011 | EP2313086A2 Controlled release topiramate formulations using intelligent polymers |
| 04/27/2011 | EP2313085A2 Immunogenic amphipathic peptide compositions |
| 04/27/2011 | EP2313084A1 An intrauterine delivery system for contraception |
| 04/27/2011 | EP2312952A1 Antimicrobial composition |
| 04/27/2011 | EP2312950A1 Compounds as kinase inhibitors |
| 04/27/2011 | EP2312949A1 N-heterocyclic m1 receptor positive allosteric modulators |
| 04/27/2011 | EP2312948A1 5-quinolinone and imidazopyridine compounds and use thereof |
| 04/27/2011 | EP2312947A1 Trpv4 antagonists |